We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Provexis Plc | LSE:PXS | London | Ordinary Share | GB00B0923P27 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.60 | 0.55 | 0.65 | 1,516,438 | 09:34:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Food Preparations, Nec | 390k | -385k | -0.0002 | -30.00 | 13.31M |
U.K. life-science business Provexis PLC (PXS.LN) has appointed John Clarke, a former executive at GlaxoSmithKline PLC (GSK.LN), as a non-executive director, it said Monday.
Clarke, who worked at GlaxoSmithKline for more than 35 years, starts his position immediately.
Provexis chairman Dawson Buck said: "[Clarke's] proven success and in-depth knowledge in the consumer healthcare and sports nutrition sectors will be an important factor as we take Provexis to its next level of development."
"I believe the recently acquired Science in Sport brand has significant growth potential and I look forward to assisting Provexis in achieving its true potential," Clarke said.
Provexis, which specializes in food and sports nutrition technologies, bought Science in Sport Ltd., a sports nutrition business, for GBP8 million last June.
At 1010 GMT, Provexis shares flat at 1.7 pence.
-By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314; jana.weigand@dowjones.com
1 Year Provexis Chart |
1 Month Provexis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions